| Identification | Back Directory | [Name]
(E)-3-(4-((E)-1-(3-chloro-1H-indol-2-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid | [CAS]
2135341-09-0 | [Synonyms]
LX-039 2-Propenoic acid, 3-[4-[2-(2-chloro-4-fluorophenyl)-1-(3-chloro-1H-indol-2-yl)-1-buten-1-yl]phenyl]- (E)-3-(4-((E)-1-(3-chloro-1H-indol-2-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid 2-hydroxy-N,N,N-trimethylethan-1-aminium (E)-3-(4-((E)-1-(3-chloro-1H-indol-2-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylate | [Molecular Formula]
C27H20Cl2FNO2 | [MOL File]
2135341-09-0.mol | [Molecular Weight]
480.36 |
| Hazard Information | Back Directory | [Uses]
LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC50 value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure. LX-039 has anti-tumor activity[1]. | [in vivo]
LX-039 (2.5 mg/kg; PO and IV; single) exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure[1].
LX-039 (6.5 mg/kg, 20 mg/kg and 60 mg/kg; PO; daily for 21 days) inhibits tumor growth in a dose-dependent manner[1].
LX-039 (1 mg/kg; PO and IV; single) displays a moderate to low clearance (Cl) plus good oral bioavailability (F%) in both rat and dog[1]. Pharmacokinetic Parameters of LX-039 in CD-1 mouse[1].
| IV | PO (2.5 mg/kg) | | Vd (L/kg) | 0.5 | | | CL (mL/min/kg) | 1.4 | | | Cmax (nM) | | 1873 | | AUC0-24 (nM·h) | | 15329 | | F (%) | | 60.1 | Pharmacokinetic Parameters of LX-039 in SD rat and Beagle dog[1]. | SD Rat | Beagle Dog | | Vd (L/kg, iv) | 2 | 0.42 | | CL (mL/min/kg, iv) | 7.7 | 0.84 | | C0, iv (nM), 1 mg/kg | 2610 | 12800 | | AUC0-24, iv (nM·h), 1 mg/kg | 4820 | 43800 | | Cmax, po (nM), 1 mg/kg | 381 | 2550 | | AUC0-24, po (nM·h), 1 mg/kg | 2700 | 24200 | | F (%) | 56 | 55 |
| [IC 50]
Estrogen receptor: 2.29 nM (EC50) | [References]
[1] Lu J, Chan CC, Sun D, et al. Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD). Bioorg Med Chem Lett. 2022;66:128734. DOI:10.1016/j.bmcl.2022.128734 |
|
|